BARCELONA, Spain, More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to clinically meaningful improvements in itch and other important patient-reported outcomes compared to placebo. “Atopic dermatitis symptoms such as itch, dry skin, severe pain and inflammation take a heavy burden on patients’ lives as well as on their wellbeing. Patients seek medicines that provide effective and well tolerated
The post Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies appeared first on Pharma Mirror Magazine.
